Manufacture of VAQTA(R), an inactivated hepatitis A vaccine, uses state-of-
the-art technologies in cell culture and bioprocessing science, which have
made it possible to routinely produce the vaccine at manufacturing scale. V
AQTA(R) consists of an attenuated strain of hepatitis A virus that is highl
y purified and formaldehyde-inactivated, then formulated with an aluminum h
ydroxide adjuvant. Process development and scale-up have resulted in a well
-characterized vaccine manufacturing process with appropriate in-process co
ntrols to assure consistent performance, and a reproducible, well-defined p
roduct. Results are presented from a series of manufacturing demonstration
lots to show consistency, as well as comparability to clinical lots prepare
d at an earlier stage in development.